Back to Resources

Articles

IND-Enabling Preclinical Development: Engineering the Bridge from Discovery to First-in-Human

Analytical Validation Across Phases: Balancing Speed, Cost, and Compliance

De-Risking Drug Product Quality Through Strategic Extractables & Leachables Assessment

Redefining Stability Protocols for Modern Small Molecule APIs

Stability and Scalability in Cell Line Development for Commercial Biologics

Accelerating Formulation Paths to First-in-Human: Why Fit-for-Purpose is the Smart Strategic Choice

From Model to Marker: An Integrated Framework for Advancing IPF Drug Development

SPR Across the Spectrum: Enabling Discovery of Small and Large Molecules

Late-Stage Modification of Peptides: Advanced Strategies for CRDMO Success

REACH: Simplifying the Complex World of Chemical Safety

Platform vs. Bespoke: Choosing the Right Early Formulation Strategy for Your Molecule

Challenges and Solutions in Cell Line Development for Biologics

High-Throughput Electrophysiology for Drug Screening and Discovery

TMT Labeling for Optimized Sample Preparation in Quantitative Proteomics

Revolutionizing new drug discovery- Harnessing AI ML Tools

Flow Chemistry vs. Batch Processes

Solutions for Mitigating Challenges in Recombinant Protein Production

Propelling Glioblastoma Research: Aragen Bioscience’s Orthotopic Model Solutions

Preclinical Model of Post – Incisional Pain for Efficacy Testing of Novel Therapeutics

Manual Whole-Cell Patch Clamp Assay for Screening NCE’s Against Voltage Gated Ion-Channels

Clinically relevant preclinical model of CFA-Induced inflammatory pain

Exploring Molecular Interactions Through Surface Plasmon Resonance

Experimental λ-Carrageenan-induced inflammatory pain model for testing novel analgesics

A Comparative Efficiency Analysis of Commercial Transfection Reagents in HEK 293 Cells

Accelerating the regulatory approval process of biosimilars by leveraging precise and reliable PK data and PD biomarker data

Streptozotocin-induced Diabetic Peripheral Neuropathic Pain Model Developed at Aragen

Experimental Chronic Constriction Injury (CCI)- induced Neuropathic Pain Model Aragen Life Sciences

Experimental pain models at Aragen Life Sciences – Spinal Nerve Ligation (SNL) Model of Neuropathic Pain

Drug-Protein Interaction: Limitless Application of Mass spectrometry in Target Engagement, Intact Mass and Peptide Mapping Analysis.

Automation to miniaturize In vitro assays to achieve superior and cost-efficient results

Targeted Protein Degradation

Pharmacokinetic study of Salbutamol through nose only exposure in CD-1 male mice

Aragen’s Bleomycin-Induced Scleroderma mouse model for preclinical testing of novel therapeutics

Industry Leading Hybridoma Technique for Accelerated Antibody Discovery

Covalent Drugs – Advantages, Challenges, And Opportunities

Mitigating CMC issues through Aragen’s holistic approach to developability assessment

Aragen’s Preclinical Oncology Capabilities – Tumor Imaging

Preclinical evaluation of Novel drug candidates against SLE in NZB/W F1 mouse models

Aragen’s Oncology solutions: Accelerate your cancer therapeutics development

RSV Challenge Model for anti-RSV therapy

Cell Line Development at Aragen: Research cell banks in 5 months

Effect of Methylprednisolone on the Systemic lupus erythematosus (SLE) in murine models

DSS-induced IBD Mouse Model for preclinical drug screening

Cell Line Development at Aragen; Accelerating speed to IND